Madrigal Pharmaceuticals Retained Earnings (Accumulated Deficit) 2010-2024 | MDGL

Madrigal Pharmaceuticals retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $-1.743B, a 42.37% increase year-over-year.

  • Madrigal Pharmaceuticals retained earnings (accumulated deficit) for 2023 were $-1.336B, a 38.81% increase from 2022.
  • Madrigal Pharmaceuticals retained earnings (accumulated deficit) for 2022 were $-0.963B, a 44.26% increase from 2021.
  • Madrigal Pharmaceuticals retained earnings (accumulated deficit) for 2021 were $-0.667B, a 56.84% increase from 2020.

Madrigal Pharmaceuticals Retained Earnings (Accumulated Deficit) 2010-2024 | MDGL

  • Madrigal Pharmaceuticals retained earnings (accumulated deficit) for 2023 were $-1.336B, a 38.81% increase from 2022.
  • Madrigal Pharmaceuticals retained earnings (accumulated deficit) for 2022 were $-0.963B, a 44.26% increase from 2021.
  • Madrigal Pharmaceuticals retained earnings (accumulated deficit) for 2021 were $-0.667B, a 56.84% increase from 2020.